在闭环人工胰腺系统中集成安全模块以防止反弹低血糖症
María F Villa-Tamayo1, Patricio Colmegna1, Marc D Breton1
1Center for Diabetes Technology, University of Virginia, Charlottesville, VA, USA.
Journal of diabetes science and technology
|November 15, 2023
概括
作为自动化胰岛素输送系统 (AID) 的新层,HypoSafe在治疗高血糖水平后显著减少反弹性低血糖症. 这项创新可以防止过度纠正,而不会对1型糖尿病管理中的葡萄糖控制产生负面影响.
科学领域:
- 生物医学工程 生物医学工程
- 内分泌学 在内分泌学.
- 糖尿病 技术 技术
背景情况:
- 自动化胰岛素输送系统 (AID) 越来越多地用于1型糖尿病 (T1D) 管理.
- 艾滋病治疗系统的一个挑战是,在摄入碳水化合物以纠正高血糖症后出现反弹性低血糖症.
- AID系统中的算法旨在进行积极的血糖控制,可能会加剧反弹低血糖症.
研究的目的:
- 引入HypoSafe,这是一个新的层,用于防止AID系统中的反弹低血糖.
- 评估HypoSafe在与先进的AID系统集成时的有效性.
主要方法:
- 根据最近的葡萄糖趋势,HypoSafe被开发用于限制胰岛素的输送.
- 该HypoSafe层被集成到弗吉尼亚大学 (UVA) AID系统中.
- 使用UVA/帕多瓦T1D模拟器对100名成年人进行模拟,包括名义和低血糖诱导的场景.
主要成果:
- 在两个模拟场景中,HypoSafe显著降低了反弹性低血糖事件 (名义:39到0;低血糖诱导:55到7).
- 该系统在低血糖症治疗后减弱了基础和玻尿酸胰岛素的输送.
- 在血糖范围 (70-180毫克/分升) 或高血糖 (>180毫克/分升) 中没有观察到对时间的显著不良影响.
结论:
- 在先进的AID系统中,HypoSafe有效地减轻反弹性低血糖症.
- 该HypoSafe层可以很容易地集成到现有的AID系统中.
- 这种方法可以提高安全性,而不会影响血糖控制目标.
相关概念视频
Hypoglycemia and Glucagon
274
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
274
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Hormones Regulating Blood Glucose
3.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.4K
Feedback Loops
57.6K
In most cases, excessive hormone production is prevented by negative feedback—a loop that starts with a stimulus inducing the release of a particular substance, like a hormone, to maintain a certain level before triggering a signal that results in a decrease in further release of the hormone.
57.6K
Glucagon-like Receptor Agonists
332
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
332
Oral Hypoglycemic Agents: Glinides
159
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
159


